Abata Therapeutics
CJ Ives is an Associate Scientist at Abata Therapeutics, with previous experience as a Senior Research Associate at Rheos Medicines and Technical Associate II at the Massachusetts Institute of Technology. CJ has a strong background in biomedical research, highlighted by a Master’s thesis at the Tulane Center for Stem Cell Research and Regenerative Medicine, focusing on the immunomodulation of adipose-derived mesenchymal stem cells. Additionally, CJ has held various teaching assistant roles at Tulane University and participated in significant research programs, including the Rackham Summer Research Opportunity Program at the University of Michigan and a Lab role at Harvard Medical School. Education includes a Master of Science-Bachelor of Science in Biomedical Engineering from Tulane University.
Abata Therapeutics
1 followers
Abata Therapeutics is bringing an entirely new approach to the treatment of autoimmune disease by engineering Tregs as targeted therapies that stop immune-mediated destruction, restore homeostasis – a state of harmony – and promote repair in the affected tissues. In addition to their lead program in progressive MS, Abata has early programs in Type 1 Diabetes (T1D) and inclusion body myositis (IBM). They bring together industry experts and deeply engaged pioneers in Treg biology, T cell receptor and antigen discovery, disease pathogenesis, and molecular and imaging biomarkers.